Article

Targeting dysregulation signatures of p53-MDM2 interactions to identify newer small molecule inhibitors for cancer therapy: Insight from computational direction

2021-02-11

Abstract excerpt

<title>Abstract</title> <p>Dysregulation of the p53-MDM2 interactions has been implicated in majority of human tumors presenting a target for finding small molecule inhibitors. In this study, a training set of 17 experimentally tested inhibitors of MDM2 was used to develop series of pharmacophore models among which a four-featured (AHRR_1) model with one hydrogen bond acceptor, one hydrophobic group and two aroma...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 86d3bc3e-4c58-56a9-8f61-8b84d9caad72
DOI: 10.21203/rs.3.rs-217761/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting dysregulation signatures of p53-MDM2 interactions to identify newer small molecule inhibitors for cancer therapy: Insight from computational directionDOI 10.21203/rs.3.rs-217761/v1Read

Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer DrugsSemantic proximity Read

Small Molecule Inhibitors of the p53-MDM2Semantic proximity Read

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trialsSemantic proximity Read

Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be AddressedSemantic proximity Read

Network Pharmacology-Based Prediction of Anticancer Targets of Mebendazole: Integrating Molecular Targets, Signaling Pathways, and Clinical EvidenceSemantic proximity Read

Predicting Anticancer Targets of Mebendazole Through Network Pharmacology: An Integrated Analysis of Molecular Targets, Signalling Pathways, and Clinical Trial EvidenceSemantic proximity Read

MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)Semantic proximity Read

Structural insights into conformational stability of ESR1 and structure base screening of new potent inhibitor for the treatment of Breast CancerSemantic proximity Read

MDM2 Antagonists and p53-Targeting Therapies in Cancer: Clinical Applications, Adverse Effects, and Resistance MechanismsSemantic proximity Read

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancerSemantic proximity Read

Structure-based pharmacophore modeling for precision inhibition of mutant ESR2 in breast cancer: A systematic computational approach.Semantic proximity Read

A data driven approach to identify ZM-447439 as a potential repurposed drug to overcome tamoxifen-resistance in breast cancerSemantic proximity Read